Brain functional changes and duloxetine treatment response in fibromyalgia: a pilot study.
|Title||Brain functional changes and duloxetine treatment response in fibromyalgia: a pilot study.|
|Publication Type||Journal Article|
|Year of Publication||2009|
|Authors||Hunter, AM, Leuchter AF, Cook IA, Abrams M, Siegman BE, Furst DE, Chappell AS|
|Journal||Pain medicine (Malden, Mass.)|
|Date Published||2009 May-Jun|
|Keywords||Adrenergic Uptake Inhibitors, Adult, Biological Markers, Brain, Catecholamines, Double-Blind Method, Drug Administration Schedule, Electroencephalography, Evoked Potentials, Female, Fibromyalgia, Frontal Lobe, Humans, Male, Middle Aged, Outcome Assessment (Health Care), Pain Measurement, Pain Threshold, Pilot Projects, Placebos, Predictive Value of Tests, Sensitivity and Specificity, Serotonin, Thiophenes, Treatment Outcome|
Serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant medications may have efficacy in relieving pain associated with fibromyalgia syndrome (FMS), even in the absence of major depressive disorder (MDD). Current practice is to use a trial-and-error treatment strategy, often requiring 8-12 weeks to determine the effectiveness of a given pharmacological intervention. The ability to predict response to antidepressant medications would facilitate clinical management of FMS. Prior work in MDD has shown that the quantitative electroencephalographic (QEEG) cordance biomarker of brain functional changes early in the course of antidepressant treatment is related to later clinical response. We hypothesized that cordance might also predict response to antidepressant medications for symptoms of FMS.
|Alternate Journal||Pain Med|